Technical Analysis for RUBY - Rubius Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 13.97 1.97% 0.27
RUBY closed up 1.97 percent on Friday, February 15, 2019, on 1.24 times normal volume.

Earnings due: Feb 19

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Up
See historical RUBY trend table...

Date Alert Name Type % Chg
Feb 15 Crossed Above 20 DMA Bullish 0.00%
Feb 15 Pocket Pivot Bullish Swing Setup 0.00%
Feb 15 Bollinger Band Squeeze Range Contraction 0.00%
Feb 15 BB Squeeze + Upper Band Touch Range Contraction 0.00%
Feb 15 Upper Bollinger Band Touch Strength 0.00%
Feb 14 Lizard Bullish Bullish Day Trade Setup 1.97%
Feb 14 Bollinger Band Squeeze Range Contraction 1.97%
Feb 14 Doji - Bullish? Reversal 1.97%
Feb 14 BB Squeeze + Lower Band Touch Range Contraction 1.97%
Feb 14 Lower Bollinger Band Touch Weakness 1.97%

Older signals for RUBY ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Rubius Therapeutics Inc is a biotechnology company that develops cellular therapies for cancer, and enzyme deficiency diseases. The Company develops Red-Cell Therapeutics (RCT) products using red platform. RCT is a red blood cell-based therapy for applications in cancer, enzyme replacement therapies, and autoimmune disease and tolerance induction. Its RCT product candidate is designed to provide various attributes, which include broad therapeutic applications, predictable bio-distribution and advantageous tolerability. It is initially focused on advancing RCT product candidates for patients suffering from rare diseases, cancer and autoimmune diseases based on three modalities - cellular shielding, potent cell-cell interaction and tolerance induction. Its product candidates in rare diseases include RTX-134 for the treatment of phenylketonuria (PKU), RTX-134 followed by RTX-Uricase and RTX-CBS for the treatment of chronic refractory gout symptomatic homocystinuria.
Biotechnology Cancer Immunology Autoimmune Diseases Rare Diseases Application Software Autoimmunity Therapies For Cancer Autoimmune Disease Computer Aided Engineering Phenylketonuria Enzyme Replacement Therapies Therapeutic Applications
Is RUBY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 33.01
52 Week Low 12.7
Average Volume 222,406
200-Day Moving Average 0.0
50-Day Moving Average 15.6914
20-Day Moving Average 13.8845
10-Day Moving Average 13.899
Average True Range 1.0183
ADX 17.45
+DI 16.7787
-DI 19.87
Chandelier Exit (Long, 3 ATRs ) 11.9651
Chandelier Exit (Short, 3 ATRs ) 15.7549
Upper Bollinger Band 14.4013
Lower Bollinger Band 13.3677
Percent B (%b) 0.58
BandWidth 7.444272
MACD Line -0.5025
MACD Signal Line -0.6323
MACD Histogram 0.1298
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.59
Resistance 3 (R3) 15.58 15.03 15.32
Resistance 2 (R2) 15.03 14.62 15.04 15.23
Resistance 1 (R1) 14.50 14.36 14.77 14.51 15.14
Pivot Point 13.95 13.95 14.08 13.96 13.95
Support 1 (S1) 13.42 13.54 13.69 13.43 12.80
Support 2 (S2) 12.87 13.28 12.88 12.71
Support 3 (S3) 12.34 12.87 12.62
Support 4 (S4) 12.35